摘要
目的:了解解放军第302医院(以下简称"我院")住院药房抗乙型肝炎病毒(hepatitis B virus,HBV)核苷(酸)类似物的使用情况及趋势,为临床合理用药提供参考。方法:采用回顾性分析法,通过住院药房信息管理系统,提取2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额,对用药频度及限定日费用等进行统计分析。结果:2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额总体呈逐年递增趋势,2015年其销售金额增长率高达11.23%(2014年为342.99万元,2015年为363.71万元)。恩替卡韦和替诺福韦的使用量均呈逐年递增趋势,而拉米夫定、阿德福韦酯和替比夫定的使用量有所降低;3年来,恩替卡韦和替比夫定的药品销售金额排序/用药频度排序的比值均为1,表明其用药人数与销售金额的同步性良好。结论:核苷(酸)类似物已经成为抗HBV的首选药物,临床上更倾向于选择高效低耐药率的阿德福韦酯、恩替卡韦和替诺福韦。临床医师应进一步规范应用核苷(酸)类似物,根据患者个体情况制订合理的治疗方案,降低耐药率。
OBJECTIVE： To investigate the application status and trend of anti-HBV nucleoside（ acid） analogues based on the clinical treatment of hepatitis B in 302 Hospital of People＇s Liberation Army,so as to provide reference for clinical rational drug application. METHODS： Retrospective analysis method was adopted,the consumption amount,comsumption sum,defined daily dose（ DDDs） and defined daily cost（ DDC） of anti-HBV nucleoside（ acid）analogues based on the clinical treatment of hepatitis B extracted from in-patient pharmacy information system during 2014-2016 were statistically analyzed. RESULTS： The consumption amount and consumption sum of anti-HBV nucleoside（ acid） analogues during 2014-2016 were in an increasing trend year to year,and the increasing rate was up to 11. 23% in 2015（ 3. 429 9 million yuan in 2014,3. 637 1 million yuan in 2015）. The consumption amount of entecavir and tenofovir was in an increasing trend,yet the clinical application of lamivudine,adefovir dipivoxil and telbivudine decreased year to year. For three years,the ratio of consumption sum ranking/medication frequence ranking was 1, which showed good synchronization between the number of patients and consumption sum.CONCLUSIONS： Nucleoside（ acid） analogues has become the preferred drug for anti-HBV,the clinic are more likely to choose effective and low-resistance drugs as entecavir,adefovir dipivoxil and tenofovir in clinical treatment. The clinicians should regulate and rational application of anti-HBV nucleoside（ acid） analogues, formulate rational treatment regimen according to the individual conditions and reduce the drug resistance.
出处
《中国医院用药评价与分析》
2017年第9期1168-1170,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
军队十二五面上课题(No.CWS11C164)
国家重大新药创制专项(No.2015ZX09J15102-004)
关键词
乙型肝炎病毒
核苷(酸)类似物
用药分析
Hepatitis B
Anti-HBV nucleoside（acid） analogues
Analysis of drug application
